August 2019 By PsychDB.com

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
cl:0-autoimmune-encephalitis [August 2019]
PsychDB.com [Immunotherapy]
cl:0-autoimmune-encephalitis [August 2019] (current)
PsychDB.com [Treatment]
Line 237: Line 237:
  
 ===== Treatment ===== ===== Treatment =====
-First-line therapy includes steroids, intravenous immune globulin (IVIG), plasma exchange (PLEX), or both IVIG and PLEX. Second-line therapy includes rituximab and cyclophosphamide. Rituximab is also increasingly being considered as a first-line therapy.+==== Immunotherapy ==== 
 +First-line therapy includes steroids, intravenous immune globulin (IVIG), plasma exchange (PLEX), or both IVIG and PLEX. Second-line therapy includes rituximab and cyclophosphamide. Rituximab is also increasingly being considered as a first-line therapy. ​Early immunotherapy improves outcomes.[([[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC4516400/​|Byrne,​ S., Walsh, C., Hacohen, Y., Muscal, E., Jankovic, J., Stocco, A., ... & King, M. (2015). Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurology-Neuroimmunology Neuroinflammation,​ 2(4), e130.]])] However, some patients may not respond to immunotherapy or may need intensive and prolonged therapies that require a tertiary or quaternary care setting.[([[https://​www.ncbi.nlm.nih.gov/​pubmed/​23290630/​|Titulaer,​ M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., ... & Aguilar, E. (2013). Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis:​ an observational cohort study. The Lancet Neurology, 12(2), 157-165.]])]